Key Drivers
- Margin Expansion
- Strong Cash Flow
- Rising Debt
AIAI Summary
ADMA should now be viewed less as a simple profitable growth story and more as a concentration-and-credibility risk: despite strong cash generation and margins, flat revenue, BIVIGAM erosion, withdrawn guidance, and legal/competitive overhangs mean the stock likely stays under pressure until ASCENIV proves durable growth.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Strong Cash Flow
- •Rising Debt
ADMA delivered exceptional profitability and cash generation with strong liquidity, but rising debt and working-capital intensity temper the still-not-cheap valuation.
Price Behavior
Key Price Behavior Insights:
- •Support Break
- •Lower Highs
- •Weak Rebound
ADMA has been in a clear downtrend over the last month, with a key support break below $10.25–$10.60 triggering a sharp drop to $7.88, and while the recent bounce is stabilizing the stock, upside remains capped near $8.47–$8.50.
Sharp drop after the $10.25–$10.60 support break to $7.88
Sentiment & News
Key News Insights:
- •Profitability up
- •Product mix shift
- •Legal overhang
ADMA showed stronger profitability and cash flow but flat sales, uneven product demand, lowered guidance, and escalating litigation risk.
The news is likely negative for the stock near term, as litigation and weaker guidance may outweigh solid earnings and cash generation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings